Medtronic Study Finds AI-Enabled Clinician Alerts Significantly Improve Valvular Heart Disease Patient Assessment and Valve Interventions

Northampton, Massachusetts / Access Newswire / May 11, 2026 / Multicenter ALERT Study Demonstrates Potential to Advance Treatment Pathways to Minimally Invasive Heart Valve Therapy for Underserved Patient Populations

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced data from the Addressing Undertreatment and Health Equity in Aortic Stenosis and Mitral Regurgitation Trial using an integrated EHR platform (ALERT) aimed at addressing health disparities and undertreatment in structural heart care. Results showed that electronic clinician notification (ECN) significantly improves the timely assessment and treatment of aortic stenosis (AS) and mitral regurgitation (MR), including treatment with transcatheter aortic valve replacement (TAVR). The findings, sponsored by Tempus, were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans and simultaneously published in the Journal of the American College of Cardiology (JACC).

“As clinicians, our priority is to ensure that patients with severe valvular heart disease receive timely treatment. Untreated, symptomatic, severe aortic stenosis carries a high risk of death within two years, especially for patients of racial and ethnic minorities and those with specific “We continue to see significant undertreatment among patients with a hemodynamic profile of 30% and 30%, which compromises our ability to scale lifesaving valve interventions across the health care system,” said Wayne Batchelor, MD, MHS, MBA. Steering Committee Chair for Inova Health System’s Medical Service Line and ALERT Study. “These findings highlight the value of real-time clinical alerts for expediting diagnosis and referral to specialists, helping to ensure that more patients receive guideline-driven, life-saving care, regardless of race, ethnicity, geography, hemodynamics, or other factors.”

The study, which utilized 765 clinicians who ordered 2,016 echocardiograms across five U.S. health systems including 35 hospitals, met its primary endpoint, defined as time to surgical or transcatheter valve intervention and subsequent multidisciplinary heart team (MHT) visit within 90 days after the index echocardiogram. Results revealed that ECN was 27% more effective than usual care in informing clinicians of a patient’s cardiovascular status (win rate, 1.27; 95% CI, 1.05-1.54; P = 0.007).

Key results at 90 days include:

Data suggest that the majority (90%) of all TAVR procedures are in Caucasian patients, making it a minimally invasive solution for AS and MR. Conversely, patients who are black, Hispanic, Asian, or other racial groups are not treated with TAVR at the same rates as other races.

Additionally, women with aortic stenosis continue to experience significant disparities in care, as they are less likely than men to receive timely evaluation and valve intervention, making improved access to minimally invasive options such as TAVR particularly important. Existing evidence suggests that this minimally invasive option may shorten hospital stay and speed recovery compared to open-heart surgery.

“The ALERT study reflects how we are building the future of structural heart care, one that is more connected, data-driven, and focused on approaches earlier in a patient’s disease progression,” said Jorie Soskin, vice president of Medtronic’s structural heart business. “By helping clinicians identify and connect patients to treatment faster, technologies like AI-enabled alerts have the potential to allow more people to benefit from life-saving treatments like TAVR, regardless of race, geography, or background. This work underscores our commitment to advancing the future of structural heart care and TAVR.”

This study leveraged Tempus Next, an AI-enabled care pathway platform that enables healthcare providers to provide next steps in a patient’s care journey. The software automatically identifies critical AS or MR patients who may meet guideline treatment criteria but for whom no treatment plan has been developed. This study evaluated the impact of electronic medical record notifications generated by Tempus Next.

Symptomatic severe aortic stenosis is a common but severe valvular heart disease that affects approximately 250,000 people annually in the United States and remains undertreated according to AHA/ACC guideline standards. Patients with symptomatic severe aortic stenosis may experience chest pain, shortness of breath, fatigue, and dizziness, which can lead to heart failure if left untreated. Mitral regurgitation (MR), another common heart valve disease, has a similar set of challenges in terms of underdiagnosis and undertreatment.

This research was funded by Tempus AI, Inc. (Chicago, IL) and Medtronic, Plc (Minneapolis, MN).

About Medtronic
A bold idea. A bolder move. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company that boldly challenges humanity’s most challenging health challenges by exploring and discovering solutions. Our mission to alleviate pain, restore health and extend lifespan unites a global team of more than 90,000 passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robots, insulin pumps, surgical instruments, patient monitoring systems, and more. Driven by diverse knowledge, insatiable curiosity, and a desire to help everyone who needs it, we deliver innovative technology that changes lives every second, hour, and day. Expect more from us for insight-driven care, people-first experiences, and a better outcome for the world. In everything we do, we are engineering something extraordinary. For more information about Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Equipped with one of the world’s largest libraries,

By integrating multimodal data and the operating systems that access and make it useful, Tempus provides AI-powered precision medicine solutions for physicians to deliver personalized patient care while accelerating the discovery, development, and delivery of optimal treatments. The goal is for each patient to benefit from the treatment of other patients previously received by giving doctors tools that learn as the company collects more data. For more information, please visit tempus.com.

Forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

contact:
Kimberly Powell
public relations
+1-202-498-2601

Ingrid Goldberg
Investor information
+1-612-505-2696

*Antia, A., Pius, R., Ndukauba, C., Remenik Zarauz, V., Olafiranye, O. (2024). Temporal trends in transcatheter aortic valve replacement utilization and outcomes across race and ethnicity: A national analysis. International Journal of Cardiology, 399, 131669.